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The aryl hydrocarbon receptor (AHR), a ligand dependent transcription 
factor, plays an important role in the recognition of xenobiotics as well as 
natural compounds such as tryptophan metabolites, dietary components and 
microbiota-derived factors1-4 and is important for maintenance of 
homeostasis at mucosal surfaces.  AHR activation induces cytochrome P4501 
(CYP1) enzymes, which function to oxygenate AHR ligands, leading to their 
metabolic clearance and detoxification5. Thus, CYP1 enzymes appear to play 
an important feedback role that curtails the duration of AHR signalling6, but 
it remains elusive whether they also regulate AHR ligand availability and 
signal intensity in vivo, processes that are of physiological importance for the 
intestinal immune system. 
Here we show that dysregulated expression of Cyp1a1 depletes the reservoir 
of natural AHR ligands, thereby generating a quasi AHR-deficient state. 
Using a Cyp1a1 reporter strain we identified intestinal epithelial cells (IECs) 
as first line responders to dietary AHR ligands. Constitutive expression of 
Cyp1a1 throughout the body or restricted specifically to IECs resulted in loss 
of AHR-dependent type 3 innate lymphoid cells (ILC3) and T helper 17 
(Th17) cells and increased susceptibility to enteric infection.  These profound 
effects of excessive AHR ligand degradation on intestinal immune system 
function could be counter-balanced by increasing the intake of AHR ligands 
in the diet. Thus, our results demonstrate that IECs serve as gatekeepers for 
the supply of AHR ligands to the host and emphasise the importance of 
feedback control in modulating AHR pathway activation.  
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It is increasingly understood that AHR signalling needs to be tightly controlled as 
prolonged activation either by ligands that resist metabolic clearance or in mice 
with constitutively active AHR has deleterious effects7-10. Enzymes of the CYP1A 
and CYP1B sub-families (CYP1) appear to be central to the control of AHR 
signalling due to their capacity for metabolising ligands and thereby terminating 
AHR activation. 
We hypothesized that excessive CYP1A1-mediated metabolic clearance of natural 
AHR ligands would cause a strong phenotype in the intestinal immune system, 
given that several immune cell types are dependent on ligand-mediated AHR 
signalling for their survival. In order to investigate this, we generated a mouse 
model with constitutive Cyp1a1 expression due to its placement under control of 
the ubiquitously active Rosa26 promoter (R26Cyp1a1) (Extended Data Fig.1). As 
proof of principle we investigated the effect of constitutive Cyp1a1 expression on 
Th17 cells, which are known to express AHR and produce IL-22 in an AHR- 
dependent manner11. Th17 cells generated from R26Cyp1a1 mice had significantly 
increased CYP1A1 enzymatic activity compared with wild-type B6 (WT) or Ahr-
deficient Th17 cells (Fig.1a). We then cultured CD4+ T cells from WT, Ahr-
deficient or R26Cyp1a1 mice under Th17 cell conditions in the presence of the 
endogenous, tryptophan-derived AHR ligand 6-formylindolo[3,2-b]carbazole 
(FICZ) and measured residual cellular FICZ levels following metabolic clearance 
over 48h of culture. FICZ levels did not decay in cultures of Ahr-deficient Th17 
cells in line with the absence of CYP1A1 induction, but cultures of R26Cyp1a1 Th17 
cells showed accelerated clearance of FICZ compared with those from WT Th17 
cells (Fig.1b). Furthermore, Th17 cells generated from R26Cyp1a1  mice showed a 
pronounced deficiency in IL-22 production to baseline AHR ligands present in 
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culture medium12 and to low concentrations of FICZ, whereas higher FICZ 
concentrations overcame this effect (Fig.1c and Extended Data Fig.2). Ahr-
deficient Th17 cells did not produce IL-22 under any condition (Fig.1c). Thus, 
constitutive CYP1A1 activity caused a decrease in AHR ligands that 
compromised induction of IL-22.   
Ahr deficiency in haematopoietic cells results in the disappearance of several cell 
types in the intestinal immune system, such as intraepithelial lymphocytes13 and 
innate lymphoid cells (ILC3)14-16. R26Cyp1a1 mice exhibited enhanced intestinal 
CYP1A1 enzyme activity (Extended Data Fig.3a) and loss of ILC3 in colon and 
small intestine similar to Ahr-deficient mice (Fig.1d,e and Extended Data Fig.3b), 
suggesting that rapid metabolic clearance of natural AHR ligands mimics an Ahr-
deficient state under homeostatic conditions. In addition, R26Cyp1a1 mice displayed 
similar developmental abnormalities to Ahr-deficient mice, such as decreased 
liver weight indicative of patent ductus venosus17 (Extended Data Fig.8). 
 
We next investigated the response of R26Cyp1a1 mice to infection with the intestinal 
pathogen Citrobacter rodentium. This infection causes severe pathology in Ahr-
deficient14-16, compared with WT mice. R26Cyp1a1 mice similarly had increased 
colon and cecal pathology scores, albeit not quite as extensive as those seen in 
Ahr-deficient mice (Fig.2a,b). While all WT mice survived the infection, Ahr-
deficient mice reached endpoint at which they had to be culled by day 9 after 
infection and R26Cyp1a1 mice survived only a few days longer (Fig.2c). C. 
rodentium penetrated deeply into the base of the crypts in Ahr-deficient and 
R26Cyp1a1 mice, whereas it mainly attached to the luminal surface of the epithelium 
in WT mice (Fig.2d).  We observed a significantly higher bacterial burden in the 
colon of Ahr-deficient and R26Cyp1a1 mice and failure to clear the infection 
resulted in dissemination of bacteria to liver and spleen (Fig.2e). IL-22 is essential 
 5 
in the defence against C. rodentium18 and the extreme susceptibility of Ahr-
deficient mice can be attributed to their lack of ILC3 as well as failure to mount a 
T cell IL-22 response. This deficiency in IL-22 as well as Th17 cells and ILC3 
was mirrored in R26Cyp1a1 mice (Fig.2f, g). Administration of recombinant IL-22–
Fc fusion protein significantly reduced bacterial burden and crypt invasion and 
prolonged survival of R26Cyp1a1 mice (Extended Data Fig.4). 
Thus, constitutive Cyp1a1 expression severely impairs the intestinal immune 
response against an enteric pathogen. 
 
If CYP1A1-mediated clearance of natural ligands produces a quasi Ahr-deficient 
state, the absence of such metabolic clearance should increase ligand availability. 
To test this, we took advantage of a mouse strain lacking the three AHR 
controlled CYP enzymes CYP1A1, CYP1A2 and CYP1B1, termed Cyp1 
knockout19. Th17 cells from Cyp1 knockout mice failed to metabolise the ligand 
FICZ and showed increased Cyp1a1 expression as well as substantially enhanced 
IL-22 production in the absence of added AhR ligands as well as reduced 
histopathology scores and bacterial burdens upon infection (Extended Data Fig.5). 
Increased ligand availability in Cyp1-deficient mice could be visualized in a 
Cyp1a1 fate-reporter mouse that reports AHR activity via induction of an eYFP 
reporter activated due to targeted insertion of Cre recombinase in the murine 
Cyp1a1 locus20. Although Cyp1-deficient mice fail to produce this enzyme, they 
still report AHR stimulation by induction of Cre mediated eYFP activation. In the 
intestine of WT Cyp1a1 reporter mice eYFP expression is scarce, reflecting the 
transient nature of AHR signalling that limits Cre induction (Fig.3a left). 
However, in Cyp1-deficient mice there was an enhanced eYFP signal in the 
intestinal epithelium (Fig.3a left). Supplementation of the diet with indole-3-
carbinol (I3C), a tryptophan-derived phytochemical that is converted to high 
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affinity AHR ligands by exposure to stomach acid21, further enhanced the eYFP 
signal in Cyp1-deficient mice (Fig.3a right).  Importantly, Cyp1a1 was 
predominantly expressed intestinal epithelial cells (Fig.3b).  
It has been shown previously that IEC specific deletion of the AHR partner 
ARNT causes systemic upregulation of Cyp1a122. Thus, we next tested the effect 
of epithelial-specific constitutive Cyp1a1 expression using Villin-cre-R26LSL-Cyp1a1 
mice (termed IECCyp1a1). Cyp1a1 expression (read out as rat Thy1 expression) was 
detectable only in CD45- IEC in these mice (Extended Data Fig.1b). Surprisingly, 
however, IECCyp1a1 mice had drastically reduced numbers of ILC3 similar to Ahr-
deficient mice and mice with constitutive Cyp1a1 expression throughout the body 
(Fig. 3c).  
In contrast, mice in which constitutive Cyp1a1 expression was restricted to 
adaptive immune cells via Rag1-Cre (Rag1Cyp1a1) had normal numbers of ILC3 
under steady state conditions (Fig.3c and Extended Data Fig.1b). 
This suggests that constitutive CYP1A1 activity in IECs, but not in adaptive 
immune cells, restricts the availability of AHR ligands to cells in the intestinal 
lamina propria, resulting in loss of AHR ligand-dependent ILC3. 
Upon infection with C. rodentium IECCyp1a1 mice rapidly succumbed (Fig. 3d) 
with increased bacterial crypt invasion (Fig. 3e) and intestinal pathology (Fig. 3f).  
C. rodentium disseminated into liver and spleen of IECCyp1a1 mice (Fig.3g) and the 
reduction of ILC3 and Th17 cells collectively affected the amount of IL-22 that 
was detectable in colon tissue (Fig.3h). In contrast, C. rodentium infected 
Rag1Cyp1a1 showed similar survival to WT mice over 14 days after infection and 
no significant differences in bacterial load, pathology score or dissemination of 
bacteria were observed (Extended Data Fig.6). While ILC3 were not affected, 
Th17 cells and their IL-22 production were strongly reduced (Extended Data 
Fig.6d). Thus, enhanced AHR ligand degradation in T cells compromises T cell 
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derived IL-22 responses, but spares ILC3. In contrast, enhanced AHR ligand 
degradation in IEC deprives ILC3 as well as T cells of AHR stimulation, thereby 
causing a more severe deficiency in immune defence against C. rodentium.  
 
 
Next we investigated whether lack of AHR ligand metabolism by non-
haematopoietic cells affects the immune response to C. rodentium infection. To 
this end we generated bone marrow chimeras by transferring WT donor bone 
marrow into irradiated WT (WT → WT) or Cyp1-deficient (WT → Cyp1-/-) 
recipients, followed by infection with C. rodentium. WT→Cyp1-/- chimeras 
showed significantly reduced pathology scores (Fig.3i) as well as bacterial loads 
(Fig.3j) as compared to WT recipients (WT→WT). Furthermore, Cyp1-/- recipients 
had increased numbers of WT donor-derived ILC3 and Th17 cells and markedly 
higher IL-22 levels (Fig3k). Thus, absence of CYP1-mediated AhR ligand 
metabolism in non-haematopoietic cells, such as IEC, results in increased ligand 
availability to intestinal immune cells and promotes resistance to enteric infection.  
Although bone marrow chimeras cannot unequivocally identify IEC as the 
responsible cell type, the data are consistent with a crucial role for IEC as 
gatekeepers for the availability of AhR ligands in the intestinal immune system. 
 
 To further substantiate the central role of CYP1A1 in controlling ligand 
availability, we investigated whether increasing AHR ligands by exogenous 
application via the diet might mitigate the loss of AHR signalling in R26Cyp1a1 
mice. This possibility seemed plausible on the basis of the in vitro data with Th17 
cells, which indicated that increasing AHR ligand dose could saturate CYP1A1-
mediated metabolic activity (Fig.1c). 
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We therefore introduced I3C to the diet of R26Cyp1a1  mice for 4 weeks prior to 
subjecting them to infection with C. rodentium. R26Cyp1a1 mice that were fed on 
control diet all succumbed to infection by day 12 and failed to clear the infection, 
whereas all mice on the I3C supplemented diet survived and had cleared the 
infection by day 14 (Fig.4a,b). Penetration of C.rodentium to the crypts was 
abrogated (Fig.4c) and the pathology scores of mice on I3C diet were drastically 
reduced (Fig.4d,e). Analysis of IL-22 levels showed recovery of IL-22 producers 
in R26Cyp1a1  mice on I3C diet (Fig.4f,g), whereas blockade of IL-22 during I3C 
diet exposure abrogated the protective effect (Fig.4h).  The beneficial effects of 
I3C are most likely due to the strong inhibition of CYP1A1 activity by its acid-
condensation products DIM and ICZ (Fig. 4i). In addition, DIM and ICZ were 
previously shown to be AHR ligands23, suggesting that reduced pathology 
observed after I3C supplementation may result from increased availability of 
endogenous ligands due to CYP1A1 inhibition as well as increased levels of 
exogenous ligands such as DIM and ICZ. ICZ like FICZ, but unlike DIM is also 
efficiently metabolised by CYP1A1 (Extended Data Fig.7). 
Thus, the excessive clearance of natural ligands, which produces a quasi Ahr-
deficient state in R26Cyp1a1 mice can be ameliorated by the supply of dietary AHR 
ligands, allowing sufficient AHR signalling to restore IL-22 production by Th17 
cells and successful eradication of C. rodentium. 
  
 9 
Discussion  
The AHR pathway is of crucial importance in the intestinal immune system as 
shown by the phenotypes of Ahr-deficient mice and genome-wide association 
studies that have identified AHR as a susceptibility locus in inflammatory bowel 
disease24. While in recent years the focus has been on AHR itself or on 
identification of ligands2,4,25, we show here that feedback regulation of the AHR 
pathway by CYP1 enzymes is a critical checkpoint that controls ligand 
availability and thereby activation of the AHR pathway.  
Dysregulated CYP1A1 activity in IECs profoundly affects the availability of 
AHR ligands in the body. Constitutive CYP1A1 activity in IEC resulted in a 
phenotype closely resembling that of Ahr-deficient mice, with the decay of 
intestinal immune cells such as ILC3 that depend on AHR signals for survival and 
impairment of the adaptive IL-22 response upon infection with intestinal 
pathogens. Conversely, lack of CYP1A1-mediated metabolism confined to IEC 
had the opposite effect, increasing protection against intestinal infection.  
Thus, IEC constitute an important checkpoint for AHR ligand availability.  
It has been shown previously in an in vitro setting that inhibition of CYP1A1 
results in a boost to AHR pathway activation due to increased availability of AHR 
ligand FICZ26. Here we demonstrate that genetic deletion of CYP1 enzymes, 
restricted to nonhaematopoetic cells, delays ligand metabolism, resulting in 
increased AHR signals in vivo. Sources of AHR ligands are abundant and include 
dietary compounds21, microbial virulence factors4 as well as AHR ligands derived 
via microbiota or host cell-mediated tryptophan metabolism2. Given that 
environmental factors such as oxidative stress, chemical pollutants and dietary 
factors have been shown to modulate CYP1 enzyme activity26, any interference 
with CYP1-mediated AHR ligand degradation has potential consequences for 
AHR pathway activation and intestinal homeostasis.  
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In this context, our finding that the intestinal pathology resulting from constitutive 
CYP1A1 activity upon infection with C. rodentium could be counter-balanced by 
increasing the intake of AHR ligands in the diet suggests that dysregulated 
CYP1A1 activity is potentially amenable to therapeutic manipulation via dietary 
supplementation.  
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Online Material and Methods 
 
Mice:  
For the generation of a constitutively active as well as an inducible Cyp1a1 allele 
the coding sequence (CDS) of Cyp1a1 was linked to the CDS of rat Thy1 using a 
2A sequence. In order to stabilize the transcriptional activity of the inserted genes, 
a woodchuck hepatitis virus-derived regulatory element in conjunction with a 
bovine growth hormone polyadenylation site was inserted 3’ of the CDSs. This 
module was inserted downstream of a cassette containing an FRT-flanked 
neomycin-resistance gene and loxP-flanked transcriptional stop elements. The 
targeting vector did not contain any artificial promoter for the expression of both 
Cyp1a1 and rat Thy1 to avoid toxicity caused by Cyp1a1 overexpression (details 
of the gene targeting and Rosa26-targeting strategy, Extended Data Figure 1). The 
targeting vector was generated by Biocytogen and used to establish R26Cyp1a1-neoR 
mice by homologous recombination in BCGEN B61-6 (C57BL/6) embryonic 
stem cells. R26Cyp1a1-neoR mice were generated after successful germ line 
transmission and backcrossed to C57BL/6J. This strain was further bred with 
mice expressing the Cre recombinase under the control of the mouse protamine 
(Prm1) promoter to obtain constitutive Cyp1a1 expression in all cell-types 
(referred to as R26Cyp1a1 mice) or with  ACTB:FLPe mice to obtain mice with a 
conditional floxed Cyp1a1 allele (referred to as R26LSL-Cyp1a1). These were crossed 
with Villin-cre mice to generate the IECCyp1a1 strain (constitutive Cyp1a1 
expression specific to intestinal epithelial cells) and Rag1-cre mice to generate the 
Rag1Cyp1a1 strain (constitutive Cyp1a1 expression specific to T and B cells).  
 
To generate the Cyp1a1 reporter strain Cyp1a1Cre mice20 (with targeted insertion 
of Cre recombinase in the murine Cyp1a1 locus) were crossed with R26ReYFP 
 12 
mice27,expressing eYFP from the ubiquitous Rosa26 promoter downstream of a 
cassette containing a loxP-flanked transcriptional stop element. This strain was 
further bred with Cyp1-/- mice19 to obtain Cyp1-/- Cyp1a1 reporter mice. All mice 
used in this study were either generated in C57BL/6 ES cells or backcrossed to 
C57BL/6 mice for at least 10 generations. All mice were bred in the Francis Crick 
Institute animal facility under specified pathogen–free conditions. All animal 
procedures were conducted under a Project Licence granted by the UK Home 
Office. Mice were age and sex-matched and more than 6 weeks old when first 
used. Both female and male mice were used in experiments.  
 
In vitro T cell differentiation  
CD4+ T cells were isolated using EasySep mouse CD4+ T cell isolation kit 
(Stemcell Technologies) with the addition of biotinylated anti-CD25 antibody 
(BioLegend). Cells were cultured in Iscove’s modified Dulbecco medium 
(IMDM, Sigma) supplemented with 2mM L-glutamine, 100 U/ml penicillin, 100 
µg/ml streptomycin, 0.05mM β-mercaptoethanol and 5% fetal calf serum 
(biosera). CD4+ T cells were differentiated in 48 well plates coated with 1 µg/ml 
anti-CD3 (clone 145-2C11, eBioscience) and 10 µg/ml soluble anti-CD28 (clone 
37.51, BioLegend) in the presence of 2ng/ml TGF-β1, 20ng/ml IL-6, 10ng/ml IL-
1b (all R&D Systems) and 10µg anti-IFN-g (BioXCell). In some cultures 6-
formylindolo[3,2-b]carbazole (FICZ, EnzoLifeSciences) was added from the start 
of culture. IL-22 cytokine levels in culture supernatants were determined by 
ELISA (eBioscience). 
 
Isolation of lamina propria cells and flow cytometry 
Colon and small intestine were cut open longitudinally and incubated in wash 
buffer (IMDM 1%FCS, 5mM EDTA, 10mM HEPES, penicillin/streptomycin, and 
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2mM DTT) for 20min at 37°C with 200rpm shaking. Colon tissue was collected, 
cut into small pieces and incubated in digestion buffer (IMDM supplemented with 
1% FCS, 10mM HEPES, penicillin/streptomycin, 50µg/ml DNAse I (Roche)) 
containing 0.4mg/ml Liberase TL (Roche) and incubated for 30min at 37°C with 
200rpm shaking. Small intestinal tissue was collected, cut into small pieces and 
incubated in digestion buffer (IMDM supplemented with 1% FCS, 10mM 
HEPES, penicillin/streptomycin, 50µg/ml DNAse I (Roche)) containing 1mg/ml 
Collagenase VIII (Sigma) and incubated for 10min at 37°C with 200rpm shaking. 
Single cell suspensions from colon and small intestine were further subjected to 
40% Percoll (Amersham) density gradient centrifugation to remove debris. For 
surface staining, cell suspensions the lamina propria were incubated with anti-
CD16/CD32 (eBioscience) and fixable live/dead cell dye (ThermoFisher) 
followed by staining with antibodies against CD11b, CD3, TCRgd, Gr1, CD11b, 
CD19, NKp46, CCR6, TCR-β (all BioLegend) and Thy1.2, CD45, CD4 (all BD 
Biosciences). For intracellular staining, single cell suspension were re-stimulated 
for 2hrs and 15min in the presence of 1ng/ml phorbol-12-myristate-13-acetate 
(PMA), 1 µg/ml ionomycin and 10 µg/ml Brefeldin A (all Sigma), washed and 
stained for surface markers as described above. Cell were then fixed in 
eBioscience Fix/Perm buffer or 4% formaldehyde (for preservation of eYFP 
fluorescence) for 30min on ice followed by permeabilization in eBioscience 
permeabilization buffer for 45min in the presence of antibodies against IL-17A, 
IL-22, T-bet (all ebioscience) and RORgt (BD Biosciences). Cells were acquired 
with a BD Fortessa X20 and analysis was performed with FlowJo v10 (Tree Star) 
software.  
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High performance liquid chromatography (HPLC) analysis of FICZ 
clearance and CYP1A1-mediated metabolism of DIM, ICZ and FICZ.  
Cellular clearance: CD4+ T cells were isolated and cultured under Th17-cell-
inducing conditions as described above and 5nM FICZ (EnzoLifeSciences) added 
at the start of culture. At various time-points cells were collected, washed in PBS 
and re-suspended in 200µl distilled water and stored at -20°C. Prior to HPLC 
analysis the cells were homogenized by sonication on ice (4 x 5 seconds) using a 
MSE Soniprep 150 equipped with an exponential probe (Measuring and Scientific 
Equipment). Extraction and chemical analysis of the homogenates, using an in-
line solid-phase extraction column coupled to a reverse-phase C18 analytical 
column, was performed as previously described26. FICZ quantity was determined 
according to a standard curve of FICZ and the results were normalized to total 
protein contents determined by Pierce Coomassie protein assay kit according to 
the manufacturer´s instructions. 
CYP1A1-mediated metabolism: Time-dependent metabolism of DIM, ICZ and 
FICZ was studied in the presence of human recombinant CYP1A1 (3.5nM) and 
the co-factor NADPH (1.0mM). Each compound (0.1µM) was incubated with 
CYP1A1 and NADPH in Tris-HCl (0.1M, pH 7.4) with EDTA (1mM) at 37°C. At 
various time-points samples were collected and acetonitrile was added to each 
sample at a final concentration of 20%, followed by vortexing (30 seconds) and 
centrifugation (10 minutes at 12x106 rpm and 4°C). Chemical analysis of the 
supernatants was performed using the same HPLC equipment as for the cellular 
clearance measurements. Separation of respective compound was achieved using 
a reverse-phase C18-AR column (ACE,  4.6 × 150mm, 5µm particle size) with a 
mobile phase consisting of water (A) and acetonitrile (B), both containing 1.5mM 
formic acid. Initially, the solvent contained 30% B, with a linear increase to 100% 
B during a period of 20 min, at a flow rate of 0.8 mL/min. DIM, ICZ and FICZ 
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was detected using excitation/emission wavelengths of 230/460 (DIM and ICZ) or 
390/525nm (FICZ). All compounds were quantified according to separate 
standard curves. To determine non-enzymatic degradation of each compound 
parallel incubations were performed where phosphate buffer was substituted for 
nadph. 
 
Ethoxyresorufin-O-Deethylase (EROD) Assay 
Intestinal tissue homogenates or CD4+ T cells cultured for 48 hours under Th17-
cell-inducing conditions were washed in PBS followed by incubation with 2 µM 
7-ethoxyresorufin in sodium phosphate buffer (50 mM, pH 8.0) at 37 °C for 30 
minutes. The reaction was terminated by adding fluorescamine (Sigma) dissolved 
in acetonitrile. Formation of resorufin (excitation/emission of 535/590nm) and 
fluorescamine (excitation/emission of 390/485nm) was quantified using a plate 
reader.  
 
Inhibition of CYP1A1 activity by I3C, DIM and ICZ. 
Effects on the ethoxyresorufin deethylase (EROD) activity of human recombinant 
CYP1A1 (2.5nM) was assayed by first pre-incubating the enzyme with the 
compound to be tested for 5 min in Tris-HCl (0.1M, pH 7.4) with EDTA (1mM) 
at 37°C followed by addition of ethoxyresorufin (0.1 µM) and NADPH (0.4 mM). 
Formation of resorufin was quantified using a multiwell plate reader with the 
excitation/emission wavelengths of 535/590 nm) and activity of the enzyme was 
determined by the rate of resorufin formation. ICZ and FICZ were purchased from 
Syntastic AB (Stockholm, Sweden).  DIM, I3C, 7-ethoxyresorufin, β-
Nicotinamide adenine dinucleotide 2′-phosphate (NADPH, N7505) and human 
recombinant cytochrome P4501A1 with P450 reductase (C3735) was purchased 
from Sigma-Aldrich. 
 16 
 
 
Immunofluorescence Microscopy 
Tissues were fixed in 4% phosphate-buffered formaldehyde solution (Fisher 
Scientific) for 24 hours. Fixed tissue sections were de-paraffinised and antigen 
retrieval performed in 0.01M sodium citrate buffer. Slides were blocked with goat 
serum, stained with mouse anti-E-cadherin (BD, 610181) and rabbit anti-
C.rodentium antiserum followed by staining with secondary antibodies (AF555-
conjugated goat-anti-rabbit and AF488-conjugated goat-anti-mouse from 
ThermoFisher). Slides were further stained with DAPI (Sigma) and mounted in 
Fluoromount-G (SouthernBiotech) and visualized using a Leica Confocal SP5-
Invert microscope. For staining of eYFP, tissue sections were fixed in 4% 
paraformaldehyde at 4°C for 16 hours followed by incubation in 30% sucrose for 
24 hours. Tissues were embedded in O.C.T. compound (VWR) followed by 
cryosectioning. Slides were blocked with rabbit serum and stained with AF488-
conjugated rabbit-anti-GFP (ThermoFisher, A21311) and AF647-conjugated 
mouse-anti-E-cadherin (BD, 560062) and visualized using a Leica Confocal SP5-
Invert microscope. Image analysis was performed in ImageJ. 
 
Infection with Citrobacter rodentium 
For C. rodentium infection a single colony of strain DBS100 (ATCC 51459; 
American Type Culture Collection) was transferred to Luria–Bertani (LB) broth 
and grown to log phase followed by centrifugation and resuspension in PBS. Mice 
were orally gavaged with 200µl of PBS containing 2x109 C. rodentium. To 
determine bacterial load, intestinal tissue pieces or faecal pellets were weighed 
and homogenized in sterile PBS and serial dilutions were plated onto Brilliance E. 
coli/coliform Selective Agar (Fisher Scientific) or LB agar plates (liver and 
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spleen) for measurement of colony-forming units (CFU). For neutralization of IL-
22, mice were injected intraperitoneally (i.p.) three times per week with 
150µg/mouse per dose monoclonal anti-IL-22 (clone 8E11, Genentech) or mouse 
IgG1 isotype control (BioXCell/2BScientific). Where indicated, mice were 
injected i.p. three times per week with 125µg/ml per dose IL-22–Fc (PRO312045, 
Genentech) or mouse IgG2a isotype control (BioXCell/2BScientific). 
 
Diet studies  
For diet studies mice were fed purified diet AIN-93M (TestDiet-IPS) or AIN-93M 
supplemented with 200ppm indole-3-carbinol (Sigma).  Mice were put on purified 
diets shortly after weaning for at least 4 weeks and maintained on the purified 
diets throughout the duration experiments. 
 
Generation of bone marrow chimeric mice 
Bone marrow was injected intravenously (2.5x106 cells per mouse) into recipient 
mice irradiated with two doses of 5Gy using a 137Cs-source. Donor bone marrow 
and recipient mice were distinguished on the basis of congenic markers. Chimeric 
mice were used in experiments 6-8 weeks following reconstitution.  
 
Colon explant cultures 
Intestinal tissue pieces (0.5-1cm length) were cultured for 24 hours in complete 
IMDM medium. IL-22 cytokine levels in the supernatants were determined by 
ELISA (eBioscience) and concentrations were normalized to the weight of the 
explants. 
 
Histological Assessment 
Tissues from distal colon and caecum were fixed in 4% phosphate-buffered 
 18 
formaldehyde solution (Fisher Scientific) for 24 hours, cut and stained with 
hematoxylin and eosin. Slides were blinded and scored (0-15) for parameters of 
inflammation and tissue damage as described in28. 
 
 
 
Statistical Analysis 
For comparisons between two groups unpaired, two-tailed Student’s t-test was 
used or when appropriate a two-way ANOVA with Dunnett’s post-test. For the 
comparison of three groups a one-way ANOVA followed by Tukey multiple 
comparison test was performed. All statistical analysis was calculated in Prism 
(GraphPad 6).  
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Extended Data Figure Legends 
Extended Data Figure 1: Generation of R26Cyp1a1 allele. 
a, The endogenous Rosa26 locus, the gene targeting vector, the targeted Rosa26 
allele including the Neo resistance gene cassette (R26Cyp1a1-neoR), the targeted 
allele (R26LSL-Cyp1a1) after FLPe-mediated recombination and the ubiquitously 
expressed R26Cyp1a1 are schematically depicted to scale. A minigene composed of 
the coding sequences of mouse Cyp1a1 and rat Thy1 connected by a 2A sequence 
followed by the woodchuck hepatitis virus derived regulatory element (WPRE) 
and a bovine growth hormone polyadenylation site (bGH pA). b,  Expression of 
rat THY1 in indicated cell types in the colon of  R26Cyp1a1 , IECCyp1a1 (Villin-Cre), 
Rag1Cyp1a1 (Rag1-Cre)  strains. 
 
Extended Data Figure 2: Altered AHR ligand availability affects IL-22 
production. 
Flow cytometry analysis of IL-17A and IL-22 expression in in vitro differentiated 
Th17 cells from indicated genotypes (day 4) exposed to DMSO, 0.01nM FICZ or 
1nM FICZ from the start of culture. 
 
Extended Data Figure 3: Altered AHR ligand affects intestinal AHR-
dependent ILC populations. 
a, CYP1A1 enzyme activity, measured by EROD assay, in intestinal tissue 
homogenates of steady state mice. b, Flow cytometry analysis of NKp46 and 
RORgt expression in CD45+ lineage negative (TCRb-CD3-TCRgd-CD19-CD11b-
Gr1-) Thy1+ live cells in the small intestine (upper panel) and phenotypic analysis 
of RORgt+NKp46- innate lymphoid cells (lower panel).  
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Results are representative of three independent experiments (n=3).  
Error bars, mean ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, as calculated by 
one-way ANOVA with Tukey post-test. 
 
Extended Data Figure 4: IL-22-Fc improves resistance to C. rodentium 
infection in R26Cyp1a1 mice. 
Mice of indicated genotypes were infected orally with ~2x109 C. rodentium and 
killed 7 days after infection or monitored for survival. a, C. rodentium burdens in 
the colon and cecum. Bars are the median and each symbol represents an 
individual mouse. b, Colon sections stained for E-Cadherin (green), C. rodentium 
(red) and DAPI (blue). Scale bars represent 100µm. c, Survival plot. 
 
Results are representative of three independent experiments.  
NS = not significant, **P < 0.01, ***P < 0.001, as calculated by one-way 
ANOVA with Tukey post-test. 
 
Extended Data Figure 5: Cyp1-deficiency enhances AHR pathway activation. 
a, CD4+ T cells from indicated genotypes were cultured under Th17-cell-inducing 
conditions and exposed to FICZ from the start of culture. Intracellular levels of 
FICZ were determined by HPLC and normalized to total protein content at the 
indicated time points. b, Frequencies of IL-22-producing cells after 4 days of 
culture under Th17-cell-inducing conditions in presence of indicated 
concentrations of FICZ. Results are representative of three independent 
experiments (n=3 per experiment, mean ± s.e.m). **P < 0.01, ***P < 0.001 as 
calculated by two-way ANOVA with Dunnett’s post-test a, or one-way ANOVA 
with Tukey post-test b. ns = not significant.  c, Flow cytometry analysis of 
Cyp1a1 (eYFP) expression by Th17 cells differentiated from indicated genotypes. 
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Plots are gated on IL-17A+ cells and numbers indicate frequencies. d, 
Representative flow cytometry plots of IL-17A and IL-22 expression in in vitro 
differentiated Th17 cells from indicated genotypes (day 4) exposed to DMSO, 
0.01nM FICZ or 1nM FICZ from the start of culture. e, Mice of indicated 
genotypes were infected orally with ~2x109 C. rodentium and bacterial burdens 
measured in the faeces at various time points. f, Pathology scores of distal colon. 
Bars are the mean and each symbol represents an individual mouse.  
 
Results are representative of at least two independent experiments (n=3).  
Error bars, mean ± s.e.m. **P < 0.01,  as calculated by Student’s t-test. 
 
Extended Data Figure 6: Effects of Rag1-Cre mediated Cyp1a1 expression on 
immunity to C. rodentium. 
Mice of indicated genotypes were infected orally with ~2x109 C. rodentium and 
killed 14 days after infection or monitored for survival. a, Survival plot. b,  C. 
rodentium burdens in the colon, cecum, liver and spleen. Bars are the median and 
each symbol represents an individual mouse. c, Pathology scores of distal colon 
and cecum. Bars are the mean and each symbol represents an individual mouse. d, 
Absolute numbers of cytokine-producing TCRb+CD4+ T cells in the colon of C. 
rodentium infected mice. 
 
Results are representative of two independent experiments.  
NS = not significant, **P < 0.01,  as calculated by Student’s t-test. 
 
Extended Data Figure 7: CYP1A1-mediated metabolism of DIM, ICZ and 
FICZ. 
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a-c, CYP1A1-mediated metabolism of a, DIM b, ICZ and c, FICZ was studied 
over time in the presence of human recombinant CYP1A1 (3.5nM) and the co-
factor NADPH (1.0mM). At indicated timepoints, samples from respective 
incubations were extracted and analysed by means of HPLC. All chemicals were 
quantified according to separate standard curves. Left panels show relative 
amount of compound remaining at each given timepoint compared to parallel 
incubations without co-factor present. Right panels show HPLC chromatograms 
at 40 minutes enzyme-incubation, with and without co-factor present. All three 
compounds were detected based on their fluorescence properties (fluorescence 
units, FLU). 
 
Results are representative of two independent experiments with two biological 
replicates at each experiment (n=4). 
 
Extended Data Figure 8: Effects of Cyp1a1 overexpression on liver 
development. 
 
a, Liver weight represented as percentage of body weight. b, Liver (left lobe) 
weight represented as percentage of body weight. Results are representative of 
two independent experiments. Bars are the mean and each symbol represents an 
individual mouse.   
*P < 0.05, **P < 0.01, ***P < 0.001, as calculated by one-way ANOVA with 
Tukey post-test.  
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Figure legends 
Figure 1: CYP1A1 controls AHR ligand availability. 
a, CYP1A1 enzyme activity, measured by EROD assay, in in vitro differentiated 
Th17 cells (day 2). b, CD4+ T cells from indicated genotypes were cultured under 
Th17-cell-inducing conditions and exposed to FICZ from the start of culture. 
Intracellular levels of FICZ were determined by HPLC and normalized to total 
protein content at indicated time points. c, IL-22 protein quantified by ELISA 
from culture supernatants of in vitro differentiated Th17 cells (day 4). d,e, 
Absolute numbers of the indicated innate lymphoid cell subsets in the small 
intestine or colon. Results are representative of three independent experiments 
(n=3 per experiment). Error bars, mean ± s.e.m. *P < 0.05, **P < 0.01, 
***P < 0.001, as calculated by one-way ANOVA with Tukey post-test a, c, d and 
e or two-way ANOVA with Dunnett’s post-test in b. ns = not significant.  
 
Figure 2: Depletion of natural AHR ligands leads to impaired immunity to C. 
rodentium. 
Mice of indicated genotypes were infected orally with ~2x109 C. rodentium and 
killed 7 days after infection or monitored for survival. a, Representative 
photomicrographs of hematoxylin and eosin (H&E) stained colon sections of C. 
rodentium infected mice. Scale bars represent 200µm. b, Pathology scores of 
distal colon and cecum. Bars are the mean and each symbol represents an 
individual mouse. c, Survival plot. d, Colon sections stained for E-Cadherin 
(green), C. rodentium (red) and DAPI (blue). Scale bars represent 100µm. e, C. 
rodentium burdens in the colon, liver and spleen. Bars are the median and each 
symbol represents an individual mouse. f, Absolute numbers of colonic RORgt+ 
ILC3 and IL-17A-producing TCRb+CD4+ T cells (mean ± s.e.m.) g, IL-22 protein 
quantified by ELISA from supernatants of distal colon organ explant cultures 
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(mean ± s.e.m.). Data represent pooled results of at least two independent 
experiments. *P < 0.05, **P < 0.01, ***P < 0.001, as calculated by one-way 
ANOVA with Tukey post-test. 
 
Figure 3: IECs serve as gatekeeper for the supply of AHR ligands to the host. 
a, Flow cytometry analysis of Cyp1a1 (eYFP) expression gated on live cells in the 
colon of mice fed control diet or diet supplemented with indole-3-carbinol (I3C) 
for two weeks (left panel) and colon sections stained for E-Cadherin (red), 
Cyp1a1 (eYFP) (green) and DAPI (blue) Scale bars represent 100µm (right 
panel). b, Histograms showing Cyp1a1 (eYFP) expression in the colon of WT 
Cyp1a1 reporter (WT) and Cyp1-/- Cyp1a1 reporter (Cyp1-/-) mice treated for two 
weeks with control or I3C diet. c, Absolute numbers of RORgt+ ILC3 in small 
intestine and colon of untreated mice of indicated genotypes. d, Survival plot of 
mice infected with ~2x109 C. rodentium. e, Colon sections stained for E-Cadherin 
(green), C. rodentium (red) and DAPI (blue) of infected mice (day 7). Scale bars 
represent 100µm. f, Representative photomicrographs of (H&E) stained colon 
sections of C. rodentium infected mice (day 7). Scale bars represent 100µm. g, C. 
rodentium burdens in the colon, liver and spleen. Bars are the median and each 
symbol represents an individual mouse. h, Absolute numbers of colonic RORgt+ 
ILC3 and Th17 cells and IL-22 protein quantified from supernatants of distal 
colon organ explant cultures (mean ± s.e.m.). i, Pathology scores (day 6) of distal 
colon and cecum in bone marrow chimeras of wildtype (WT→WT) or Cyp1 
deficient (WT→Cyp1-/-) recipients. Bars are the mean and each symbol represents 
an individual mouse. j, C. rodentium burdens in the colon. Bars are the median 
and each symbol represents an individual mouse. k, Absolute numbers of WT 
donor-derived colonic RORgt+ ILC3 and Th17 cells and IL-22 protein in distal 
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colon organ explant cultures (mean ± s.e.m.) Results are representative of three 
independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 as calculated by 
Student’s t-test or one-way ANOVA with Tukey post-test. ns = not significant.  
Figure 4: Dietary AHR ligands restore immunity to C. rodentium. 
R26Cyp1a1 mice fed purified diet (Control diet) or purified diet supplemented with 
indole-3-carbinol (I3C diet) were infected orally with ~2x109 C. rodentium and 
monitored for survival. a, Survival plot. b, C. rodentium burdens in the faeces at 
indicated time points. c, Colon sections of C. rodentium infected mice stained for 
E-Cadherin (green), C. rodentium (red) and DAPI (blue). Scale bars represent 
100m m. d, Representative photomicrographs of H&E stained colon sections. 
Scale bars represent 100m m. e, Pathology scores of distal colon and cecum. Bars 
are the mean and each symbol represents an individual mouse. f, Flow cytometry 
analysis of IL-17A and IL-22 expression in TCRb+CD4+ T cells from the colon of 
C. rodentium infected mice.  g, Absolute numbers of cytokine-producing 
TCRb+CD4+ T cells cells in the colon C. rodentium infected mice. h, Survival 
plot of R26Cyp1a1 mice fed I3C diet and treated with anti-IL-22 blocking antibody 
or isotype control. i, Concentration-dependent inhibition of human recombinant 
CYP1A1 enzyme activity by I3C, di-indolylmethane (DIM) and 6-
formylindolo[3,2-b] (FICZ). Concentrations causing 50% inhibition (IC50) is 
stated in respective plot.  
Results are representative of three independent experiments. Error bars, mean ± 
s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001, as calculated by Student’s t-test. 
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